Bicycle Therapeutics Reveals Updated Clinical Results Across Oncology Pipeline
14/9 10:15
(RTTNews) - Bicycle Therapeutics plc. (BCYC) announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bi...